IMA Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$741 Sell
202
-220
-52% -$732 ﹤0.01% 1231
2026
Q1
$1.29K Buy
422
+117
+38% +$452 ﹤0.01% 738
2025
Q4
$1.25K Buy
+305
New +$1.51K ﹤0.01% 749

Other funds holding RXRX

IMA Advisory Services's RXRX Position: Q2 2026 in Review

IMA Advisory Services reduced its Recursion Pharmaceuticals (RXRX) stake by 52% in Q2 2026, selling an estimated $732 and leaving 202 shares worth $741. The position accounts for ﹤0.01% of the portfolio, ranked #1231.

IMA Advisory Services first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.29K in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • IMA Advisory Services held 202 shares of Recursion Pharmaceuticals worth $741 as of Q2 2026.
  • IMA Advisory Services sold 220 Recursion Pharmaceuticals shares in Q2 2026, an estimated $732.
  • Recursion Pharmaceuticals made up ﹤0.01% of IMA Advisory Services's portfolio in Q2 2026, its #1231 holding.
  • IMA Advisory Services first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • IMA Advisory Services's Recursion Pharmaceuticals position peaked at $1.29K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on IMA Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.